Peter Salzmann - 07 Jan 2022 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role
Chief Executive Officer, Director
Signature
/s/ Eva Renee Barnett, attorney-in-fact for Peter Salzmann
Issuer symbol
IMVT
Transactions as of
07 Jan 2022
Net transactions value
-$907,396
Form type
4
Filing time
11 Jan 2022, 09:49:41 UTC
Previous filing
14 Sep 2021
Next filing
14 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale $907,396 -125,158 -18% $7.25 577,955 07 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which 37.5% of these RSUs vested on January 1, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney